西曲替尼联合纳武利尤单抗治疗晚期或转移性尿路上皮癌的2期研究
该开放标签、多队列2期研究评估西曲替尼联合纳武利尤单抗在晚期/转移性尿路上皮癌中的疗效与安全性,共纳入244例患者。在既往铂类化疗患者中,CPI初治者客观缓解率为32.1%,CPI难治者为14.9%,CPI和ADC难治者为5.4%。联合方案安全性可控,但未产生有临床意义的客观缓解。
要点
- 在既往铂类化疗的CPI初治患者中,客观缓解率为32.1%,中位无进展生存期为3.9个月。
- 在CPI难治患者中,客观缓解率为14.9%;在CPI和ADC难治患者中,客观缓解率为5.4%。
- 3级治疗相关不良事件发生率为51.2%,4级为3.3%,出现1例治疗相关死亡(心力衰竭)。
核心结论
- 西曲替尼联合纳武利尤单抗在晚期/转移性尿路上皮癌的八个队列中安全性可控,但未产生有临床意义的客观缓解率。
研究设计与样本
- 516-003试验(NCT03606174)为开放标签、多队列2期研究,评估西曲替尼联合纳武利尤单抗在晚期/转移性尿路上皮癌患者中的疗效与安全性。
- 共纳入244例患者,根据既往是否接受CPI、铂类化疗或抗体药物偶联物治疗分为八个队列,中位随访时间为14.1至38.2个月。
- 治疗方案为西曲替尼(游离碱胶囊120 mg每日一次或苹果酸盐胶囊100 mg每日一次)联合纳武利尤单抗(240 mg每2周或480 mg每4周静脉给药)。
主要发现
- 在既往接受铂类化疗的患者中,CPI初治患者(n=53)的客观缓解率为32.1%,中位无进展生存期为3.9个月。
- 在既往接受铂类化疗的患者中,CPI难治患者(n=67)的客观缓解率为14.9%,中位无进展生存期为3.9个月。
- 在既往接受铂类化疗的患者中,CPI和ADC难治患者(n=56)的客观缓解率为5.4%,中位无进展生存期为3.7个月。
- 所有队列中,3级治疗相关不良事件发生率为51.2%,4级为3.3%,出现1例治疗相关死亡(心力衰竭)。
- 免疫相关不良事件发生率为50.4%,6.1%的患者因治疗相关不良事件停用西曲替尼/纳武利尤单抗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Checkpoint inhibitor therapy (CPI) has demonstrated survival benefits in urothelial carcinoma (UC); however, not all patients benefit from CPI due to resistance. Combining sitravatinib, a multitargeted receptor tyrosine kinase inhibitor of TYRO3, AXL, and MERTK (TAM) receptors and VEGFR2, with CPI may improve antitumor responses. Our objective was to assess the efficacy and safety of sitravatinib plus nivolumab in patients with advanced/metastatic UC. METHODS: The 516-003 trial (NCT03606174) is an open-label, multicohort phase 2 study evaluating sitravatinib plus nivolumab in patients with advanced/metastatic UC enrolled in eight cohorts depending on prior treatment with CPI, platinum-based chemotherapy (PBC), or antibody-drug conjugate (ADC). Overall, 244 patients were enrolled and treated with sitravatinib plus nivolumab (median follow-up 14.1-38.2 mo). Sitravatinib (free-base capsules 120 mg once daily [QD] or malate capsule 100 mg QD) plus nivolumab (240 mg every 2 wk/480 mg every 4 wk intravenously). KEY FINDINGS AND LIMITATIONS: The primary endpoint was objective response rate (ORR; RECIST v1.1). The secondary endpoints included progression-free survival (PFS) and safety. The Predictive probability design and confidence interval methods were used. Among patients previously treated with PBC, ORR, and median PFS were 32.1% and 3.9 mo in CPI-naïve patients (n = 53), 14.9% and 3.9 mo in CPI-refractory patients (n = 67), and 5.4% and 3.7 mo in CPI- and ADC-refractory patients (n = 56), respectively. Across all cohorts, grade 3 treatment-related adverse events (TRAEs) occurred in 51.2% patients and grade 4 in 3.3%, with one treatment-related death (cardiac failure). Immune-related adverse events occurred in 50.4% patients. TRAEs led to sitravatinib/nivolumab discontinuation in 6.1% patients. CONCLUSIONS AND CLINICAL IMPLICATIONS: Sitravatinib plus nivolumab demonstrated a manageable safety profile but did not result in clinically meaningful ORRs in patients with advanced/metastatic UC in the eight cohorts studied. PATIENT SUMMARY: In this study, the combination of two anticancer drugs, sitravatinib and nivolumab, resulted in manageable side effects but no meaningful responses in patients with bladder cancer.
引用
- Msaouel P, Sweis RF, Bupathi M, et al. A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma. Eur Urol Oncol. 2023. PMID: 38105142. doi:10.1016/j.euo.2023.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。